SCHEMBL3979178

SCHEMBL3979178

CCc1c(-c2ccccc2)coc1C(=O)OC

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.44
HTT P42858 1/20 0.41
ALDH1A1 P00352 3/20 0.40
LMNA P02545 2/20 0.40
MEN1 O00255 1/20 0.40
HPGD P15428 1/20 0.40
KMT2A Q03164 1/20 0.40
PRKCZ Q05513 1/20 0.40
EGFR P00533 1/20 0.40
ADORA3 P0DMS8 2/20 0.40
NPC1 O15118 1/20 0.40
POLB P06746 1/20 0.40
GABRA1 P14867 1/20 0.40
GABRG2 P18507 1/20 0.40
GABRB3 P28472 1/20 0.40
GABRA5 P31644 1/20 0.40
GABRA3 P34903 1/20 0.40
TSHR P16473 1/20 0.40
MAPT P10636 1/20 0.39
FGFR1 P11362 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3974640 0.90 HTT (0.42) L3MBTL1HTTALDH1A1LMNAMEN1
SCHEMBL27605336 0.84 POLB (0.40) HTTALDH1A1MEN1KMT2AADORA3
SCHEMBL3982069 0.82 MEN1 (0.41) L3MBTL1HTTALDH1A1LMNAMEN1
SCHEMBL3977063 0.80 LMNA (0.45) HTTALDH1A1LMNAMEN1HPGD
SCHEMBL3975619 0.79 NPC1 (0.37) HTTALDH1A1LMNAMEN1HPGD
SCHEMBL28962190 0.79 SLC6A4 (0.45) L3MBTL1HTTALDH1A1LMNAMEN1
SCHEMBL3983743 0.78 HTT (0.40) HTTALDH1A1LMNAMEN1HPGD
SCHEMBL3977057 0.73 PTGS1 (0.42) HTTALDH1A1LMNAMEN1HPGD
SCHEMBL9672778 0.73 HTT (0.46) HTTALDH1A1LMNAMEN1HPGD
SCHEMBL28550466 0.73 SLC6A3 (0.53) HTTALDH1A1LMNAMEN1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514452-B2 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same DAINIPPON PHARMACEUTICAL CO., LTD (JP) 2009-04-07 US disclosed
US-20050171196-A1 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2005-08-04 US disclosed
EP-1489077-A1 2-FURANCARBOXYLIC ACID HYDRAZIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 2004-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171196-A1 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same GLP1R, GCGR, GPR119 L3MBTL1 2556/4885HTT 1770/4885ALDH1A1 1389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.